- Case report
- Open Access
Gardner's syndrome in a 40-year-old woman: successful treatment of locally aggressive desmoid tumors with cytotoxic chemotherapy
© Bhama et al; licensee BioMed Central Ltd. 2006
- Received: 14 October 2005
- Accepted: 17 December 2006
- Published: 17 December 2006
Desmoid tumors that present as a part of Gardener's syndrome can present very difficult management problems.
We report a case of intra-abdominal desmoid tumor causing distal small bowel obstruction that complicated the management of a more proximal enterocutaneous fistula from the jejunum. After failure of more conventional management options including imatinib, the patient's disease responded to doxorubicin and ifosfamide. The response resolved the bowel obstruction and allowed small intestinal resection to resolve the enterocutaneous fistula.
Systemic cytotoxic therapy with doxorubicin and ifosfamide can be useful for patients with complications from intra-abdominal desmoid tumor.
- Familial Adenomatous Polyposis
- Small Bowel Obstruction
- Cytotoxic Chemotherapy
Gardner's syndrome includes familial adenomatous polyposis with extracolonic manifestations, such as osteomas, supernumerary teeth, fibrous dysplasia of the skull, fibromas, and epidermoid cysts. Desmoid tumors, also known as "aggressive fibromatosis", can have a significant impact on the morbidity and mortality of patients with Gardner's syndrome. Locally aggressive desmoid tumors can impinge on surrounding structures, causing symptoms and organ impairment. When treatment is indicated, these tumors should be surgically resected with wide margins. However, resection is often followed by recurrence, and resection of some lesions would cause unacceptable deficits. Although desmoid tumors have no metastatic potential, systemic therapy with a variety of agents can be helpful. Cytotoxic chemotherapy is effective in some cases refractory to more conservative treatment options. We report a case of a 40 year-old woman with Gardner's Syndrome and desmoid tumors causing an enterocutaneous fistula with distal small bowel obstruction, successfully managed with a strategy that included cytotoxic chemotherapy.
A 40-year-old-woman with a history of Gardner's Syndrome status post prophylactic colectomy presented with an enterocutaneous fistula and for reevaluation of desmoid tumors. She had three previous abdominal operations including a prophylactic colectomy in 1992. In 1995, she had a resection of small intestine and marginal resection of associated desmoid tumors causing small bowel obstruction. In 2002, an emergent resection of small intestine and desmoid tumors for intestinal perforation removed only a portion of the diffuse mesenteric disease. This operation was complicated by an enterocutaneous fistula from the jejunum that subsequently healed with conservative care. She had no adjuvant radiation therapy at any point. Estrogen and progesterone receptor expression of the tumors was never assessed.
Approximately 10% of patients with FAP develop desmoid tumors as part of their extra-colonic manifestations . Although they are histologically benign and typically slow-growing, desmoid tumors do have the capacity to become locally aggressive. Treatment for desmoid tumor is indicated for symptoms, risk to adjacent structures, or cosmesis. In this case, treatment of desmoid tumor was indicated for small bowel obstruction caused by desmoid tumor growth.
Surgical resection with negative pathologic margins is optimal for treatment of most symptomatic desmoid tumors . Post-operative adjuvant radiation therapy may be useful when macroscopic residual tissue is present, particularly in areas with relatively radiation-tolerant surrounding normal tissues. For patients with large tumors or impediments to complete resection, neoadjuvant management with non-cytotoxic or cytotoxic agents may be of benefit. Intra-abdominal desmoids in particular are often not amenable to margin negative resection, and in some instances cytotoxic chemotherapy has achieved favorable results [3, 4] In this case, chemotherapy reduced the size of a tumor causing distal obstruction, allowing bowel resection to resolve an enterocutaneous fistula.
For lesions requiring systemic therapy, hormonal therapy including tamoxifen, toremifine, raloxifene, and progestinal agents have been effective in a subset of patients [5–7]. Non-steroidal anti-inflammatory drugs may be used alone or in combination with tamoxifen . Sulindac is a commonly used NSAID to treat desmoid tumors. Imatinib (Gleevec), a tyrosine kinase inhibitor, has been effective in treatment for desmoid and a phase II multicenter trial investigating the activity of this agent is underway [9, 10].
Cytotoxic chemotherapy is indicated when other measures fail. There can be a significant increase in treatment-related morbidity, which may be justified in some clinical settings. Typically, initial treatment is low-dose systemic chemotherapy to limit side-effects. For instance, treatment with methotrexate and vinblastine given every 7–10 days for several months has stabilized advanced and aggressive disease in some patients . However, responses are often slow and generally occur over many months.
More intensive cytotoxic chemotherapy, such as the combination of doxorubicin and dacarbazine, has been effective in patients who have unresectable disease that is refractory to endocrine therapy, steroids and NSAIDs [12, 13]. Combination chemotherapy using doxorubicin and ifosfamide produced a relatively rapid radiologic and clinical response in our patient.
Although desmoid tumors have no metastatic potential, they may often be locally aggressive, increasing the morbidity and mortality of patients with Gardner's syndrome. As we gain experience in detecting and treating adenomatous disease early, we can expect the extra-colonic manifestations of Gardner's syndrome to play a greater role in the prognosis of these patients. For desmoid tumors, treatment options extend beyond surgical resection, radiation therapy, and non-cytotoxic systemic therapies and can include cytotoxic chemotherapy to the benefit of our patients.
Written consent was obtained from the patients for publication of this case.
- Clark SK, Phillips RKS: Desmoids in familial adenomatous polyposis. Br J Surg. 1996, 83: 1494-504.View ArticlePubMedGoogle Scholar
- Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA: Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999, 17: 158-167.PubMedGoogle Scholar
- Poritz LS, Blackstein M, Berk T, Gallinger S, McLeod RS, Cohen Z: Extended follow-up of patients treated with cytotoxic chemotherapy for intra-abdominal desmoid tumors. Dis Colon Rectum. 2001, 44: 1268-1273. 10.1007/BF02234783.View ArticlePubMedGoogle Scholar
- Clark SK, Neale KF, Landgrebe JC, Phillips RK: Desmoid tumors complicating familial adenomatous polyposis. Br J Surg. 1999, 86: 1185-1189. 10.1046/j.1365-2168.1999.01222.x.View ArticlePubMedGoogle Scholar
- Wilcken N, Tattersall MH: Endocrine therapy for desmoid tumors. Cancer. 1991, 68: 1384-1388. 10.1002/1097-0142(19910915)68:6<1384::AID-CNCR2820680634>3.0.CO;2-F.View ArticlePubMedGoogle Scholar
- Tonelli F, Ficari F, Valanzano R, Brandi ML: Treatment of desmoids and mesenteric fibromatosis in familial adenomatous polyposis with raloxifine. Tumori. 2003, 89: 391-396.PubMedGoogle Scholar
- Bus PJ, Verspaget HW, van Krieken JH, de Roos A, Keizer HJ, Bemelman WA, Vasen HF, Lamers CB, Griffioen G: Treatment of mesenteric desmoid tumors with the anti-oestrogenic agent toremifene: case histories and an overview of the literature. Eur J Gastroenterol Hepatol. 1999, 11: 1179-1183. 10.1097/00042737-199910000-00018.View ArticlePubMedGoogle Scholar
- Tsukada K, Church JM, Jagelman DG, Fazio VW, McGannon E, George CR, Schroeder T, Lavery I, Oakley J: Noncytotoxic drug therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis. Dis Colon Rectum. 1992, 35: 29-33. 10.1007/BF02053335.View ArticlePubMedGoogle Scholar
- Mace J, Sybil Biermann J, Sondak V, McGinn C, Hayes C, Thomas D, Baker L: Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer. 2002, 95: 2373-2379. 10.1002/cncr.11029.View ArticlePubMedGoogle Scholar
- Baker LH, Wathen K, Chugh R, Thomas D, Thall PF, Maki RG, Samuels BL, Meyers PA, Priebat DA, Benjamin RS: Activity of imatinib mesylate in desmoid tumors: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial (abstract). J Clin Oncol. 2004, 22 (14S): 9013-[Abst]Google Scholar
- Azzarelli A, Gronchi A, Bertulli R, Tesoro JD, Baratti D, Pennacchioli E, Dileo P, Rasponi A, Ferrari A, Pilotti S, Casali PG: Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer. 2001, 92: 1259-1264. 10.1002/1097-0142(20010901)92:5<1259::AID-CNCR1446>3.0.CO;2-Y.View ArticlePubMedGoogle Scholar
- Lynch HT, Fitzgibbons R, Chong S, Cavalieri J, Lynch J, Wallace F, Patel S: Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner's syndrome. Dis Colon Rectum. 1994, 37: 260-267. 10.1007/BF02048164.View ArticlePubMedGoogle Scholar
- Patel SR, Evans HL, Benjamin RS: Combination chemotherapy in adult desmoid tumors. Cancer. 1993, 72: 3244-3247. 10.1002/1097-0142(19931201)72:11<3244::AID-CNCR2820721118>3.0.CO;2-D.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.